Global sarcoma drug market is anticipated to grow at a CAGR of 8.3% during the forecast period (2024-2031). The rising FDA approvals for sarcoma drugs are a key factor driving the growth of the global sarcoma drugs market. For instance, in May 2022, Washington University School of Medicine developed an investigational drug to attack synovial sarcoma, a rare soft tissue tumor. The drug triggers cell death and is set for a phase 1 clinical trial to assess its safety and effectiveness in patients with sarcomas that have spread beyond the original tumor site.
Browse the full report description of “Sarcoma Drug Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Targeted Therapy, Immuno Therapy, and Others), by Disease Indication (Soft Tissue Sarcoma (STS), Bone Sarcoma, Gastrointestinal Stromal Tumors (GIST), and Kaposi Sarcoma) and by Distribution Channel (Hospital Pharmacy, Retail pharmacy, and Online Pharmacy) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/sarcoma-drug-market
Further, in November 2021, Aadi Bioscience's Fyarro, its first commercial product, was approved by the FDA for adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors. The FDA approved Fyarro based on data from a phase 2 registrational trial, with 29.9% of patients achieving an overall response.
Furthermore, in February 2020, Epizyme's Tazverik, a first-in-class EZH2 inhibitor, was approved for treating epithelioid sarcoma (ES), a rare soft tissue tumor. The drug, which is expected to gain market value through wider use in more lucrative cancer settings, is expected to be available in the US for approximately 300 patients.
Market Coverage
• The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Treatment Type
o By Disease Indication
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape - Bayer AG, Eli Lilly and Co., Novartis AG, Merck & Co., Inc., and Pfizer Inc. among others.
Key questions addressed by the report.
Global Sarcoma Drug Market Report Segment
By Treatment Type
By Disease Indication
By Distribution Channel
Global Sarcoma Drug Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/sarcoma-drug-market